Initiation of OPERA-01 pivotal Phase 3 monotherapy clinical trial on track; expecting to enroll first patient in fourth quarterNew clinical data for palazestrant to be presented in the fourth quarter.
SAN FRANCISCO, Aug. 02, 2023 Olema Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for.
SAN FRANCISCO, July 05, 2023 Olema Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for.